We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CLC bio Tests Next Generation Sequencing Solution on African Tuberculosis Data

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CLC bio Tests Next Generation Sequencing Solution on African Tuberculosis Data"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

CLC bio has joined forces with the first center for High Throughput DNA Sequencing in Africa, Inqaba Biotechnical Industries (Pty) Ltd., in an effort to help fight tuberculosis on the African continent. Together CLC bio and inqaba biotec will assemble and analyze data from multiple tuberculosis strains, sequenced on inqaba biotec’s Genome Sequencer FLX system.

CLC bio, is in the final stage of development of their upcoming CLC Genomics Workbench, which is a new workbench aimed at next generation sequencing and whole genome assembly.

The workbench will support all next generation sequencing platforms, such as Roche GS FLX (454), Illumina Gene Analyzer System (Solexa), and SOLiD Analyzer from Applied Biosystems from the start - with Helicos and others to be included in the near future.

Dr. Oliver Preisig, Executive Director at Inqaba Biotechnical Industries, states, 'The consortium’s goal is to find the genetic differences between different strains of Mycobacterium tuberculosis. We target our genome sequencing on XDR (Extreme Drug Resistant) and MDR (Multi Drug Resistant) strains of the bacterium. Having assembled the genomes of these strains we can find the strains’ specific markers and develop a PCR test that could bring much faster diagnosis for proper treatment. This means we have an urgent need for whole genome sequencing, and look forward to CLC bio’s upcoming workbench, which will provide an intuitive and fast solution.'